We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Randox and Bosch Healthcare Alliance Targets COVID-19 Testing

By LabMedica International staff writers
Posted on 28 Oct 2020
Print article
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)
A partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) aims to alter the testing landscape in both laboratory and non-laboratory settings toward the rapid detection of COVID-19.

The collaborative approach of Randox and Bosch Healthcare focuses on safety precautions as well as solutions to both analyzing and differentiating COVID-19 from other viral respiratory diseases. Their combined efforts have resulted in the launch of the Vivalytic, an all-in-one solution for molecular diagnostics, consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection on a single platform.

The Viral Respiratory Infection array (VRI) rapidly detects the SARS-CoV-2 virus that causes COVID-19 while simultaneously differentiating between nine other respiratory diseases, in less than two and a half hours. Randox, Bosch Healthcare and R-Biopharm also offer various analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among the fastest PCR tests worldwide.

Randox and Bosch Healthcare offer a range of testing strategies, including the upcoming SARS-CoV-2 Pooling test. The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentralized testing approach for effectively and efficiently monitoring and detecting viral infection from the onset. The solution is capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously with a capacity for processing more than 160 patient samples a day. Sample pooling allows more people to be tested quickly using fewer testing resources. The pooling can be done at the level of a ward, medical specialty, social bubble, or a group of colleagues. It also has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces.
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.